Table 1. Contribution Rates of the 13 Compounds to the hTR-Agonist Activities in Site1 (%)a.
| (%) | Jun. | Jul. | Aug. | Sep. | Oct. | Nov. |
|---|---|---|---|---|---|---|
| TRIAC | 61 | 87 | 102 | 60 | 123 | 96 |
| TETRAC | - | - | - | - | - | - |
| GC-1 | - | - | 3.5 × 10–2 | - | - | - |
| T3 | 3.3 × 10–3 | 1.5 × 10–2 | 1.5 × 10–2 | 4.2 × 10–3 | 2.3 × 10–2 | - |
| T4 | - | - | - | - | - | - |
| DITPA | - | - | - | - | - | - |
| 3-Cl-T3 | - | 8.8 × 10–3 | - | - | - | - |
| rT3 | - | 3.7 × 10–3 | 1.8 × 10–3 | 2.4 × 10–3 | 2.6 × 10–3 | - |
| acetyl T4 | - | - | - | - | - | - |
| T1 | 3.2 × 10–3 | 3.1 × 10–3 | 4.7 × 10–4 | 1.0 × 10–6 | 4.7 × 10–4 | 1.6 × 10–4 |
| TCBPA | 4.9 × 10–4 | 5.1 × 10–4 | 7.4 × 10–4 | 4.3 × 10–4 | 5.3 × 10–4 | 4.0 × 10–4 |
| TBBPA | 1.1 × 10–4 | 1.2 × 10–4 | 1.9 × 10–4 | 1.2 × 10–4 | 1.4 × 10–4 | 2.1 × 10–4 |
| triclabendazole | 7.5 × 10–7 | 3.5 × 10–5 | 2.2 × 10–5 | 7.5 × 10–7 | 3.2 × 10–5 | - |
| TCRs | 61 | 87 | 102 | 60 | 123 | 96 |
| (%) | Dec. | Jan. | Feb. | Mar. | Apr. | May |
|---|---|---|---|---|---|---|
| TRIAC | 148 | 92 | 116 | 136 | 106 | 79 |
| TETRAC | - | - | - | - | - | - |
| GC-1 | - | - | - | - | - | - |
| T3 | - | 1.2 × 10–2 | 1.6 × 10–2 | - | - | 0.18 |
| T4 | - | 1.2 × 10–2 | - | - | - | 3.8 × 10–2 |
| DITPA | - | - | - | - | - | - |
| 3-Cl-T3 | 6.1 × 10–2 | 1.5 × 10–2 | - | - | 6.4 × 10–2 | - |
| rT3 | 3.9 × 10–3 | 5.8 × 10–3 | 8.4 × 10–3 | - | 6.9 × 10–3 | - |
| acetyl T4 | - | - | - | - | - | - |
| T1 | 3.5 × 10–3 | - | 2.6 × 10–3 | 1.9 × 10–3 | 2.8 × 10–3 | - |
| TCBPA | 5.5 × 10–4 | 4.5 × 10–4 | 8.6 × 10–4 | - | 8.6 × 10–4 | 2.2 × 10–4 |
| TBBPA | 3.0 × 10–4 | 1.8 × 10–4 | 1.5 × 10–4 | 9.7 × 10–5 | 9.1 × 10–5 | 7.7 × 10–5 |
| triclabendazole | - | - | - | 5.4 × 10–6 | 3.8 × 10–6 | - |
| TCRs | 148 | 92 | 116 | 136 | 106 | 79 |
All values indicate the contribution rate of each compound to the hTR-agonist activity in the STP effluents by the TR yeast cell assay. Hyphen means not detected by LC–MS/MS, and the maximum contribution rates calculated from LOQ (%) are given below: TRIAC = 0.43, TETRAC = 0.25, GC-1 = 6.9 × 10–2, T3 = 2.1 × 10–3, T4 = 2.1 × 10–3, DITPA = 7.9 × 10–4, 3-Cl-T3 = 1.2 × 10–3, rT3 = 6.7 × 10–4, acetyl T4 = 2.0 × 10–4, T1 = 2.6 × 10–5, TCBPA = 1.3 × 10–5, TBBPA = 8.9 × 10–6, and triclabendazole = 5.2 × 10–7. All values are represented as the mean of three replicates (n = 3). The concentrations in the STP effluents quantified by LC–MS/MS are shown in Table S6 (ng/L). The hTR-agonist activities in Site1 are shown in Table S8. A comparison with the 13 compound concentrations as T3 equivalent and the hTR-agonist activities is given in Table S9 (ng-T3 eq/L). TCR is the total contribution rate (%). The dose–response and standard curves by the yeast assay and LC–MS/MS, respectively, are shown in Figure S1.